Critical Reviews in Oncology Hematology
IF
6.31
Papers
3,910
Papers 3,824
1 page of 383 pages (3,824 results)
Newest
#1Meng-Yu Chen (CMU: China Medical University)
#2Yue-Can Zeng (HMU: Hainan Medical University)
Abstract null null Lung cancer has attracted much attention because of its high morbidity and mortality worldwide. The advent of immunotherapy approaches, especially the application of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of lung cancer, but a novel and unexpected pattern of treatment response—— pseudoprogression, has been observed simultaneously which complicates the routine clinical evaluation and management. However, manifestations of pseudoprogression va...
Source
Abstract null null Cancer derives from alterations of pathways responsible for cell survival, differentiation and proliferation. Dysfunctions of mechanisms protecting genome integrity can promote oncogenesis but can also be exploited as therapeutic target. Poly-ADP-Ribose-Polymerase (PARP)-inhibitors, the first approved targeted agents able to tackle DNA damage response (DDR), have demonstrated antitumor activity, particularly when homologous recombination impairment is present. Despite the rele...
Source
#1Ming Sheng Lim (LGH: Launceston General Hospital)
#2Simon McRae (LGH: Launceston General Hospital)H-Index: 16
The coagulopathy of COVID-19 is characterised by significantly elevated D Dimer and fibrinogen, mild thrombocytopenia and a mildly prolonged PT/APTT. A high incidence of thrombotic complications occurs despite standard thromboprophylaxis. The evidence to date supports immunothrombosis as the underlying mechanism for this coagulopathy which is triggered by a hyperinflammatory response and endotheliopathy. A hypercoagulable state results from endothelial damage/activation, complement activation, p...
Source
#1Tracie Cheng (Griffith University)H-Index: 3
#2Alfred King-Yin Lam (Griffith University)H-Index: 61
Last. Vinod Gopalan (Griffith University)H-Index: 32
view all 3 authors...
Polycyclic aromatic hydrocarbon (PAHs) are molecules that contaminate meat products during the high-temperature cooking of meat. This study reviewed the pathogenic roles of meat derived polycyclic aromatic hydrocarbons in the carcinogenesis of colorectal cancer (CRC). Ingested PAHs undergo xenobiotic metabolism resulting in the activation of genotoxic metabolites that can induce DNA damage in the colorectum. Genetic polymorphisms in PAH xenobiotic enzymes are linked to the risk of CRC and sugges...
Source
#1Unnati Modi (CUG: Central University of Gujarat)
#2Pooja Makwana (CUG: Central University of Gujarat)
Last. Rajesh Vasita (CUG: Central University of Gujarat)H-Index: 12
view all 3 authors...
The multistep metastasis process is carried out by the combinatorial effect of the stromal cells and the cancerous cells and plays vital role in the cancer progression. The scaffold/physical cues aided 3D cancer spheroid imitates the spatiotemporal organization and physiological properties of the tumor. Understanding the role of the key players in different stages of metastasis, the molecular cross-talk between the stromal cells and the cancer cells contributing in the advancement of the metasta...
Source
#1Amin Doosti-Irani (TUMS: Tehran University of Medical Sciences)H-Index: 10
#2Mohammad Ali Mansournia (TUMS: Tehran University of Medical Sciences)H-Index: 44
Last. Kourosh Holakouie-Naieni (TUMS: Tehran University of Medical Sciences)H-Index: 12
view all 6 authors...
We aimed to compare available palliative treatments in terms of survival and to rank these treatments for esophageal cancer. Web of Science, Medline, Scopus, Cochrane Library and Embase were searched. The risk of bias was judged using Cochrane's tools. Statistical heterogeneity was assessed using the Chi2 test and was quantified by I2. The results were summarized using the hazard ratio (HR). The rank probability for each treatment was calculated using the p-score. Nineteen RCTs met the eligibili...
Source
#1Deniz Can Guven (Hacettepe University)H-Index: 7
#2Taha Koray Sahin (Hacettepe University)H-Index: 5
Last. Suayib Yalcin (Hacettepe University)H-Index: 23
view all 6 authors...
Abstract null null Pancreatic cancer is a deadly disease with limited therapeutic options. Several strategies are being investigated to improve disease management, including the early diagnosis of recurrences and treatment tailoring by better prognosis estimation. Circulating tumor DNA (ctDNA) could be a promising tool in this regard, although the data is limited. Therefore, we conducted a systemical review and meta-analysis of the published studies on the association of ctDNA and survival outco...
Source
#1Jennifer Ben Shimol (TAU: Tel Aviv University)H-Index: 3
#2Yuli Guzman-PradoH-Index: 4
Last. Tima Davidson (TAU: Tel Aviv University)H-Index: 11
view all 4 authors...
BACKGROUND Radiotherapy is frequently added to immune checkpoint inhibitors (ICI) when treating melanoma. We sought to describe the efficacy of combination ICI and palliative radiotherapy (pRT) and assess safety, focusing on immune related adverse events (irAE). METHODS A systematic search for studies investigating the combination of pRT and ICI was conducted. RESULTS Five hundred-two articles were identified; nine met inclusion criteria. Improvements in objective response rate (p = 0.02), compl...
Source
Abstract null null In the era of precision medicine, monoclonal antibodies and small molecule inhibitors are the mainstays of the biological therapy in patients with solid tumors. However, resistance to treatment and the “undruggability” of certain key oncogenic proteins emerged as major limitations and jeopardize the clinical benefit of modern therapeutic approaches. Targeted protein degraders are novel molecules entering the early phase of clinical development that exploit the intracellular ub...
Source
#1Nabih Naim (SJU: Saint Joseph's University)
#2Sara Moukheiber (SJU: Saint Joseph's University)
Last. Hampig Raphael Kourie (SJU: Saint Joseph's University)H-Index: 18
view all 4 authors...
Abstract null null RAS is the most frequently mutated oncogene in human cancer. Scientists attempted for decades to target this protein or its pathways, however, all the attempts failed and RAS was labeled as “undruggable”. With KRAS-G12C covalent inhibitors entering clinical trials, the myth of this “undruggable” RAS is fading away. In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated locally advanced...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.